THE AVAILABILITY OF ANTIHYPERTENSIVE DRUG IN ERA OF NHI: A STUDY IN THE PRIMARY HEALTH CARE CENTRE JAKARTA-INDONESIA
DOI:
https://doi.org/10.22159/ijap.2021.v13s2.18Keywords:
NHI, Drug availability, Drug used, Drug stock, Antihypertensive drugAbstract
Objective: The study was carried out to observe the impact of NHI to availability, usage, stock of antihypertensive drug enrolled in a national formulary in one of the primary health care centre in Jakarta.
Methods: A longitudinal time series design was performed retrospectively to analyse the availability, usage, and stock of antihypertensive drug. The data period was from January 2013 (1 y before NHI) to December 2015 (2 y after NHI). The Independent-Samples T or Mann-Whitney test was conducted to compare these parameters before and after NHI.
Results: We found amlodipine 5 mg and 10 mg tablet, hydrochlorothiazide 25 mg tablet, captopril 12.5 mg and 25 mg tablet, nifedipine 10 mg tablet were available in Primary Health Care. These drug were generic and tablet dosage form. The most common drug used was captopril and Nifedipine, respectively. The highest availability was diuretic hydrochlorothiazide. The availability of amlodipine 5 mg and 10 mg tablet, captopril 12.5 mg tablet increased significantly (P<0.05) after NHI was implemented. Moreover, hydrochlorothiazide decreased (P<0.05) as well. The usage of amlodipine and hydrochlorothiazide risen (P<0.05) but the nifedipine decreased (P<0.05) after NHI. All stock of antihypertensive except captopril 25 mg different significantly (P<0.05) after the application of NHI.
Conclusion: This study highlights the implementation of NHI impacted the availability, usage, and stock of antihypertensive drug enrolled in national formulary.
Downloads
References
2. Ministry of Health. Regulation of MoH No. 27 about technical guideline INA-CBGs system. Jakarta; 2014.
3. Ministry of Health. The regulation of MoH No. 59 about standardize of rate of healthcare in the implementation of NHI. Jakarta; 2014.
4. PT ASKES. Price list and ceiling price of medicine. Jakarta; 2011.
5. Ministry of Health. National Formulary. No. HK.02.02/ MOH/1523/2015. Jakarta; 2015.
6. Presidential Decree. Indonesian presidential decree No. 111 changes of Indonesian presidential decree No. 12 Y 2013 about health insurance. Jakarta; 2013.
7. Servan Mori E, Heredia Pi I, Montañez Hernandez J. Access to medicines by seguro popular beneficiaries: pending tasks towards universal health coverage. PLoS One 2015;10:e0136823.
8. Mousnad MA, Ibrahim MIM, Palaian S, Shafie AA. Medicines utilization and trends in Sudan between 2006 and 2010. Trop J Pharm Res 2017;16:1717-28.
9. Jung YW, Pak H, Lee I, Kim EH. The effect of the diagnosis-related group payment system on quality of care in the field of obstetrics and gynecology among Korean Tertiary Hospitals. Yonsei Med J 2018;59:539-45.
10. The regulation of ministry of health RI No. 63 y 2014. The procurement of drugs based on e-catalogue. Jakarta; 2014.
11. National health survey. Central data and information Ministry of Health the Republic of Indonesia. Jakarta; 2014.
12. James PA, Oparil S, Carter BL, Cushman WC, Dennison Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama 2014;311:507-20.
13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219.
14. The regulation of Ministry of Health RI no. HK.02.02/ MoH/068/1/2010. The obligation of generic drugs used in the public health care facilities. Jakarta; 2010.
15. Ofori Asenso R, Brhlikova P, Pollock AM. Prescribing indicators at primary health care centers within the WHO African region: a systematic analysis (1995–2015). BMC Public Health 2016;16:724.
16. World Health Organization. The world medicines situation. Geneva: World Health Organization; 2004.
17. World Health Organization, Harvard Medical School and Harvard Pilgrim Health. Medicines use in primary care in developing and transitional countries Fact Book summarizing results from studies reported between 1990 and 2006. Geneva: World Health Organization; 2009.
18. Caceres MC, Moyano P, Farinas H, Cobaleda J, Pijierro A, Darado P, et al. Trends in antihypertensive drug use in spanish primary health care 1990–2012. Adv Pharmacoepidemiol Drug Saf 2015;3:172.
19. Xu H, He Y, Xu L, Yan X, Dai H. The availability of Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data. Int J Clin Pharmacol Ther 2015;53:430-7.
20. Beg MA, Dutta S, Varma A, Kant R, Bawa S, Anjoom M, et al. Study on drug prescribing pattern in hypertensive patients in a tertiary care teaching hospital at Dehradun, Uttarakhand. Int J Med Sci Public Health 2014;3:922–6.
21. Al-Drabah E, Irshaid Y, Yasein N, Zmeili S. Prescription pattern of antihypertensive drugs in family practice Clinics at Jordan University Hospital. Med Sci 2013;2:469–88.
22. Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens 2016;22:1-8.
23. Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of antihypertensive drugs for patients attending the outpatient department of hiwot fana specialized University Hospital, Harar, Eastern Ethiopia. Drug Des Dev Ther 2015;9:519–23.